drugset / Trial / NCT02972632

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

NCT02972632

Phase 4 Completed 123 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).

Timeline

Start
2016-12-22
Primary completion
2018-02-06
Completion
2018-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg Oral
Subject Vortioxetine Unknown 20 mg Oral